# US 2026/0152468 A1 · Novel ceramide, preparation method therefor, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0152468 A1
- Document ID: US20260152468A1
- Status: Published application
- Kind: A1
- Application number: 19/119,508
- Filed: 2023-10-10
- Published: 2026-06-04
- Earliest claimed: 2022-10-10
- Assignees: Shenzhen Dikeman Biotechnology Co., Ltd.
- Applicants: Shenzhen Dikeman Biotechnology Co., Ltd.
- Inventors: Chaowen YANG; Liu YE
- Web page: https://patentgrep.com/patent/US20260152468A1

## CPC

- C07C 235/08: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- A61K 8/42: Amides
- A61K 8/68: Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K 31/231: having one or two double bonds
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 39/00: General protective or antinoxious agents
- A61P 39/06: Free radical scavengers or antioxidants
- A61Q 19/08: Anti-ageing preparations
- C07C 231/02: from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 2800/74: Biological properties of particular ingredients
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present disclosure belongs to the technical field of biological medicines. Disclosed is a novel ceramide which has a structure represented as formula I Further disclosed in the present disclosure are a preparation method for and the use of the ceramide. The present disclosure uses naturally-sourced and readily-available 10-hydroxycarboxylic acid as a starting raw material to construct the ceramide having a novel structure. The preparation method has a simple and convenient synthetic route and is suitable for large-scale production. Meanwhile, the obtained ceramide shows more excellent effects in the aspects of tissue repair, anti-inflammatory repair, tissue healing, moisturizing and anti-aging, and thus can be used in the fields of health care products, cosmetics and drugs.

## Claims

### Claim 1

A ceramide having a structure of formula I, or enantiomers or diastereoisomers thereof:

### Claim 2 (depends on 1)

A preparation method for the ceramide according to claim 1, comprising the steps of:
obtaining a compound S2 from reaction of a compound S1 with TBDPSC1;
obtaining a compound S3 from reaction of the compound S2 with 4-nitrophenyl trifluoroacetate;
obtaining a compound S4 by deprotection of the compound S3;
obtaining a compound S5 from reaction of the compound S4 with linolelaidoyl chloride;
obtaining the ceramide from reaction of the compound S5 with phytosphingosine.

### Claim 3 (depends on 2)

The method according to claim 2, wherein a molar ratio of the compound S1 to TBDPSC1 is 1:(1 to 3); a molar ratio of the compound S2 to 4-nitrophenyl trifluoroacetate is 1:(1 to 3); a molar ratio of the compound S4 to the linolelaidoyl chloride is 1:(1 to 3); and a molar ratio of the compound S5 to the phytosphingosine is 1:(1 to 2).

### Claim 4 (depends on 1)

Use of the ceramide according to claim 1 in cosmetics, health products or pharmaceuticals.

### Claim 5 (depends on 4)

The use according to claim 4, wherein the ceramide has tissue-repairing effects; and the cell viability is more than 114% when the ceramide is at a concentration of 0.0625 mM, and/or the cell viability is more than 120% when at a concentration of 0.5 mM.

### Claim 6 (depends on 4)

The use according to claim 4, wherein the ceramide has anti-inflammatory repair effects: the inhibition rate on cytokine IL-6 is above 46% when the ceramide is at a concentration of 0.1 mM, and/or the inhibition rate on cytokine IL-6 is above 73% when the ceramide is at a concentration of 0.2 mM, and/or the inhibition rate on cytokine IL-6 is above 86% when the ceramide is at a concentration of 0.4 mM, and/or the inhibition rate on cytokine IL-6 is above 94% when the ceramide is at a concentration of 0.8 mM, and/or the inhibition rate on cytokine IL-6 is above 97% when the ceramide is at a concentration of 1.0 mM.

### Claim 7 (depends on 4)

The use according to claim 4, wherein the ceramide has tissue-healing effects, and the cell healing rate is more than 74% when the ceramide is at a concentration of 0.08 mM.

### Claim 8 (depends on 4)

The use according to claim 4, wherein the ceramide has moisturizing effects: the expression level of AQP3 is more than 112% relative to a solvent control group when the ceramide is at a concentration of ceramide of 0.4 nM; the expression level of AQP3 is more than 133% relative to a solvent control group when the ceramide is at a concentration of ceramide of 0.8 mM; the expression level of AQP3 is more than 147% relative to a solvent control group when the ceramide is at a concentration of ceramide of 1.6 mM.

### Claim 9 (depends on 4)

The use according to claim 4, wherein the ceramide has anti-aging effects; the inhibition rate on elastase is above 18% when the ceramide is at a concentration of 0.4 mM, and the inhibition rate on elastase is above 22% when the ceramide is at a concentration of 0.8 mM, and the inhibition rate on elastase is above 25% when the ceramide is at a concentration of 1.0 mM.

### Claim 10 (depends on 1)

A composition comprising the ceramide according to claim 1, isomers, pharmaceutically acceptable salts, hydrates or solvates thereof as an active ingredient.
